Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor

Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

Peter L. Greenberg, Zhuoxin Sun, Kenneth B. Miller, John M. Bennett, Martin S. Tallman, Gordon Dewald, Elisabeth M. Paietta, Richard Van Der Jagt, Jessie Houston, Mary L. Thomas, David Cella, Jacob M. Rowe

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC;n = 53) versus SC alone (n = 57) for the treatment of anemic patients with lower-risk myelodysplastic syndromes. The response rates in the EPO versus SC alone arms were 36% versus 9.6%, respectively, at the initial treatment step, 47% in the EPO arm, including subsequent steps. Responding patients had significantly lower serum EPO levels (45% vs 5% responses for levels < 200 mU/mL vs ≥ 200 mU/mL) and improvement in multiple quality-of-life domains. With prolonged follow-up (median, 5.8 years), no differences were found in overall survival of patients in the EPO versus SC arms (median, 3.1 vs 2.6 years) or in the incidence of transformation to acute myeloid leukemia (7.5% and 10.5% patients, respectively). Increased survival was demonstrated for erythroid responders versus nonresponders (median, 5.5 vs 2.3 years). Flow cytometric analysis showed that the percentage of P-glycoprotein+ CD34+ marrow blasts was positively correlated with longer overall survival. In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation.

Original languageEnglish (US)
Pages (from-to)2393-2400
Number of pages8
JournalBlood
Volume114
Issue number12
DOIs
StatePublished - 2009

Fingerprint

Oncology
Myelodysplastic Syndromes
Granulocyte Colony-Stimulating Factor
Erythropoietin
Survival
Acute Myeloid Leukemia
Therapeutics
Incidence
P-Glycoprotein
Bone Marrow
Quality of Life
Safety
Serum

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor : Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). / Greenberg, Peter L.; Sun, Zhuoxin; Miller, Kenneth B.; Bennett, John M.; Tallman, Martin S.; Dewald, Gordon; Paietta, Elisabeth M.; Van Der Jagt, Richard; Houston, Jessie; Thomas, Mary L.; Cella, David; Rowe, Jacob M.

In: Blood, Vol. 114, No. 12, 2009, p. 2393-2400.

Research output: Contribution to journalArticle

Greenberg, Peter L. ; Sun, Zhuoxin ; Miller, Kenneth B. ; Bennett, John M. ; Tallman, Martin S. ; Dewald, Gordon ; Paietta, Elisabeth M. ; Van Der Jagt, Richard ; Houston, Jessie ; Thomas, Mary L. ; Cella, David ; Rowe, Jacob M. / Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor : Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). In: Blood. 2009 ; Vol. 114, No. 12. pp. 2393-2400.
@article{412a89b296514d44996a5aa6da938508,
title = "Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)",
abstract = "This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC;n = 53) versus SC alone (n = 57) for the treatment of anemic patients with lower-risk myelodysplastic syndromes. The response rates in the EPO versus SC alone arms were 36{\%} versus 9.6{\%}, respectively, at the initial treatment step, 47{\%} in the EPO arm, including subsequent steps. Responding patients had significantly lower serum EPO levels (45{\%} vs 5{\%} responses for levels < 200 mU/mL vs ≥ 200 mU/mL) and improvement in multiple quality-of-life domains. With prolonged follow-up (median, 5.8 years), no differences were found in overall survival of patients in the EPO versus SC arms (median, 3.1 vs 2.6 years) or in the incidence of transformation to acute myeloid leukemia (7.5{\%} and 10.5{\%} patients, respectively). Increased survival was demonstrated for erythroid responders versus nonresponders (median, 5.5 vs 2.3 years). Flow cytometric analysis showed that the percentage of P-glycoprotein+ CD34+ marrow blasts was positively correlated with longer overall survival. In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation.",
author = "Greenberg, {Peter L.} and Zhuoxin Sun and Miller, {Kenneth B.} and Bennett, {John M.} and Tallman, {Martin S.} and Gordon Dewald and Paietta, {Elisabeth M.} and {Van Der Jagt}, Richard and Jessie Houston and Thomas, {Mary L.} and David Cella and Rowe, {Jacob M.}",
year = "2009",
doi = "10.1182/blood-2009-03-211797",
language = "English (US)",
volume = "114",
pages = "2393--2400",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor

T2 - Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

AU - Greenberg, Peter L.

AU - Sun, Zhuoxin

AU - Miller, Kenneth B.

AU - Bennett, John M.

AU - Tallman, Martin S.

AU - Dewald, Gordon

AU - Paietta, Elisabeth M.

AU - Van Der Jagt, Richard

AU - Houston, Jessie

AU - Thomas, Mary L.

AU - Cella, David

AU - Rowe, Jacob M.

PY - 2009

Y1 - 2009

N2 - This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC;n = 53) versus SC alone (n = 57) for the treatment of anemic patients with lower-risk myelodysplastic syndromes. The response rates in the EPO versus SC alone arms were 36% versus 9.6%, respectively, at the initial treatment step, 47% in the EPO arm, including subsequent steps. Responding patients had significantly lower serum EPO levels (45% vs 5% responses for levels < 200 mU/mL vs ≥ 200 mU/mL) and improvement in multiple quality-of-life domains. With prolonged follow-up (median, 5.8 years), no differences were found in overall survival of patients in the EPO versus SC arms (median, 3.1 vs 2.6 years) or in the incidence of transformation to acute myeloid leukemia (7.5% and 10.5% patients, respectively). Increased survival was demonstrated for erythroid responders versus nonresponders (median, 5.5 vs 2.3 years). Flow cytometric analysis showed that the percentage of P-glycoprotein+ CD34+ marrow blasts was positively correlated with longer overall survival. In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation.

AB - This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC;n = 53) versus SC alone (n = 57) for the treatment of anemic patients with lower-risk myelodysplastic syndromes. The response rates in the EPO versus SC alone arms were 36% versus 9.6%, respectively, at the initial treatment step, 47% in the EPO arm, including subsequent steps. Responding patients had significantly lower serum EPO levels (45% vs 5% responses for levels < 200 mU/mL vs ≥ 200 mU/mL) and improvement in multiple quality-of-life domains. With prolonged follow-up (median, 5.8 years), no differences were found in overall survival of patients in the EPO versus SC arms (median, 3.1 vs 2.6 years) or in the incidence of transformation to acute myeloid leukemia (7.5% and 10.5% patients, respectively). Increased survival was demonstrated for erythroid responders versus nonresponders (median, 5.5 vs 2.3 years). Flow cytometric analysis showed that the percentage of P-glycoprotein+ CD34+ marrow blasts was positively correlated with longer overall survival. In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation.

UR - http://www.scopus.com/inward/record.url?scp=70350512346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350512346&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-03-211797

DO - 10.1182/blood-2009-03-211797

M3 - Article

VL - 114

SP - 2393

EP - 2400

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -